Clinicopathological correlates and prognostic significance of KRAS mutation status in a pooled prospective cohort of epithelial ovarian cancer

Diagnostic Pathology

Volumn 8, Issue 1, 2013, Pages

  Nodin, Björn ^a   Zendehrokh, Nooreldin ^a   Sundström, Magnus ^b   Jirström, Karin ^a  

^a LUND UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

KRAS mutation; Ovarian cancer; Prognosis

Indexed keywords

KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN; TUMOR MARKER;

AGED; ARTICLE; COLLOID CARCINOMA; FEMALE; GENETICS; HUMAN; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MUTATION; NEOPLASM; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY;

ADENOCARCINOMA, MUCINOUS; AGED; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MUTATION; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879220149     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-8-106     Document Type: Article

References (49)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249. 10.3322/caac.20006, 19474385.
2. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet 2009, 374(9698):1371-1382. 10.1016/S0140-6736(09)61338-6, 19793610.
3. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 2003, 3(1):11-22.
4. Settleman J, Narasimhan V, Foster LC, Weinberg RA. Molecular cloning of cDNAs encoding the GAP-associated protein p190: implications for a signaling pathway from ras to the nucleus. Cell 1992, 69(3):539-549. 10.1016/0092-8674(92)90454-K, 1581965.
5. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988, 16(16):7773-7782. 10.1093/nar/16.16.7773, 338489, 3047672.
6. Laghi L, Orbetegli O, Bianchi P, Zerbi A, Di Carlo V, Boland CR, Malesci A. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene 2002, 21(27):4301-4306. 10.1038/sj.onc.1205533, 12082617.
7. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004, 164(5):1511-1518. 10.1016/S0002-9440(10)63708-X, 1615664, 15111296.
8. Geyer JT, Lopez-Garcia MA, Sanchez-Estevez C, Sarrio D, Moreno-Bueno G, Franceschetti I, Palacios J, Oliva E. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases. Am J Surg Pathol 2009, 33(8):1157-1163. 10.1097/PAS.0b013e3181a902e1, 19542870.
9. Prat J. Ovarian carcinomas: five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012, 460(3):237-249. 10.1007/s00428-012-1203-5, 22322322.
10. Ichikawa Y, Nishida M, Suzuki H, Yoshida S, Tsunoda H, Kubo T, Uchida K, Miwa M. Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 1994, 54(1):33-35.
11. Enomoto T, Weghorst CM, Inoue M, Tanizawa O, Rice JM. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 1991, 139(4):777-785. 1886299, 1656759.
12. McCluggage WG. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis. Pathology 2011, 43(5):420-432. 10.1097/PAT.0b013e328348a6e7, 21716157.
13. Lalwani N, Prasad SR, Vikram R, Shanbhogue AK, Huettner PC, Fasih N. Histologic, molecular, and cytogenetic features of ovarian cancers: implications for diagnosis and treatment. Radiographics 2011, 31(3):625-646. 10.1148/rg.313105066, 21571648.
14. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 2011, 42(7):918-931. 10.1016/j.humpath.2011.03.003, 3148026, 21683865.
15. Berglund G, Elmstahl S, Janzon L, Larsson SA. The Malmo Diet and Cancer Study. Design feasibility. J Intern Med 1993, 233(1):45-51. 10.1111/j.1365-2796.1993.tb00647.x, 8429286.
16. Berglund G, Eriksson KF, Israelsson B, Kjellstrom T, Lindgarde F, Mattiasson I, Nilsson JA, Stavenow L. Cardiovascular risk groups and mortality in an urban swedish male population: the Malmo Preventive Project. J Intern Med 1996, 239(6):489-497. 10.1046/j.1365-2796.1996.483819000.x, 8656142.
17. Nodin B, Zendehrokh N, Brandstedt J, Nilsson E, Manjer J, Brennan DJ, Jirstrom K. Increased androgen receptor expression in serous carcinoma of the ovary is associated with an improved survival. J Ovarian Res 2010, 3:14. 10.1186/1757-2215-3-14, 2902477, 20565760.
18. Ehlen A, Brennan DJ, Nodin B, O'Connor DP, Eberhard J, Alvarado-Kristensson M, Jeffrey IB, Manjer J, Brandstedt J, Uhlen M, et al. Expression of the RNA-binding protein RBM3 is associated with a favourable prognosis and cisplatin sensitivity in epithelial ovarian cancer. J Transl Med 2010, 8:78. 10.1186/1479-5876-8-78, 2936876, 20727170.
19. Notani D, Gottimukkala KP, Jayani RS, Limaye AS, Damle MV, Mehta S, Purbey PK, Joseph J, Galande S. Global regulator SATB1 recruits beta-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol 2010, 8(1):e1000296. 10.1371/journal.pbio.1000296, 2811152, 20126258.
20. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998, 4(7):844-847. 10.1038/nm0798-844, 9662379.
21. Nodin B, Hedner C, Uhlen M, Jirstrom K. Expression of the global regulator SATB1 is an independent factor of poor prognosis in high grade epithelial ovarian cancer. J Ovarian Res 2012, 5(1):24. 10.1186/1757-2215-5-24, 3472180, 22992394.
22. Ehlen A, Nodin B, Rexhepaj E, Brandstedt J, Uhlen M, Alvarado-Kristensson M, Ponten F, Brennan DJ, Jirstrom K. RBM3-regulated genes promote DNA integrity and affect clinical outcome in epithelial ovarian cancer. Transl Oncol 2011, 4(4):212-221. 3140008, 21804916.
23. Caduff RF, Svoboda-Newman SM, Ferguson AW, Johnston CM, Frank TS. Comparison of mutations of Ki-RAS and p53 immunoreactivity in borderline and malignant epithelial ovarian tumors. Am J Surg Pathol 1999, 23(3):323-328. 10.1097/00000478-199903000-00012, 10078924.
24. Sundov D, Caric A, Mrklic I, Gugic D, Capkun V, Hofman ID, Mise BP, Tomic S. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas. Diagn Pathol 2013, 8:21. 10.1186/1746-1596-8-21, 3570323, 23388101.
25. Ozer H, Yenicesu G, Arici S, Cetin M, Tuncer E, Cetin A. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagn Pathol 2012, 7:124. 10.1186/1746-1596-7-124, 3523067, 22995373.
26. Garrett AP, Lee KR, Colitti CR, Muto MG, Berkowitz RS, Mok SC. k-ras mutation may be an early event in mucinous ovarian tumorigenesis. Int J Gynecol Pathol 2001, 20(3):244-251. 10.1097/00004347-200107000-00007, 11444200.
27. Vang R, Shih Ie M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009, 16(5):267-282. 10.1097/PAP.0b013e3181b4fffa, 2745605, 19700937.
28. Auner V, Kriegshauser G, Tong D, Horvat R, Reinthaller A, Mustea A, Zeillinger R. KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 2009, 9:111. 10.1186/1471-2407-9-111, 2671522, 19358724.
29. Mayr D, Hirschmann A, Lohrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006, 103(3):883-887. 10.1016/j.ygyno.2006.05.029, 16806438.
30. Grisham RN, Iyer G, Garg K, DeLair D, Hyman DM, Zhou Q, Iasonos A, Berger MF, Dao F, Spriggs DR, et al. BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 2013, 119(3):548-554. 10.1002/cncr.27782, 22930283.
31. Fabjani G, Kriegshaeuser G, Schuetz A, Prix L, Zeillinger R. Biochip for K-ras mutation screening in ovarian cancer. Clin Chem 2005, 51(4):784-787. 10.1373/clinchem.2004.041194, 15788786.
32. Jarboe E, Folkins A, Nucci MR, Kindelberger D, Drapkin R, Miron A, Lee Y, Crum CP. Serous carcinogenesis in the fallopian tube: a descriptive classification. Int J Gynecol Pathol 2008, 27(1):1-9. 10.1097/pgp.0b013e31814b191f, 18156967.
33. Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol 2003, 90(2):378-381. 10.1016/S0090-8258(03)00264-6, 12893203.
34. Singer G, Oldt R, Cohen Y, Wang BG, Sidransky D, Kurman RJ, Shih Ie M. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003, 95(6):484-486. 10.1093/jnci/95.6.484, 12644542.
35. Hannibal CG, Vang R, Junge J, Kjaerbye-Thygesen A, Kurman RJ, Kjaer SK. A binary histologic grading system for ovarian serous carcinoma is an independent prognostic factor: a population-based study of 4317 women diagnosed in Denmark 1978-2006. Gynecol Oncol 2012, 125(3):655-660. 10.1016/j.ygyno.2012.02.028, 3358352, 22370600.
36. Stewart CJ, Leung Y, Walsh MD, Walters RJ, Young JP, Buchanan DD. KRAS mutations in ovarian low-grade endometrioid adenocarcinoma: association with concurrent endometriosis. Hum Pathol 2012, 43(8):1177-1183. 10.1016/j.humpath.2011.10.009, 22305241.
37. Hermanek P, Wittekind C. Residual tumor (R) classification and prognosis. Semin Surg Oncol 1994, 10(1):12-20. 10.1002/ssu.2980100105, 8115781.
38. Wong KK, Lu KH, Malpica A, Bodurka DC, Shvartsman HS, Schmandt RE, Thornton AD, Deavers MT, Silva EG, Gershenson DM. Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. Int J Gynecol Pathol 2007, 26(4):404-409. 10.1097/pgp.0b013e31803025cd, 17885490.
39. Escobar J, Klimowicz AC, Dean M, Chu P, Nation JG, Nelson GS, Ghatage P, Kalloger SE, Kobel M. Quantification of ER/PR expression in ovarian low-grade serous carcinoma. Gynecol Oncol 2013, 128(2):371-376. 10.1016/j.ygyno.2012.10.013, 23103384.
40. Lee P, Rosen DG, Zhu C, Silva EG, Liu J. Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 2005, 96(3):671-677. 10.1016/j.ygyno.2004.11.010, 15721410.
41. Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 2007, 18(5):1051-1059.
42. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature 2008, 452(7184):187-193. 10.1038/nature06781, 18337816.
43. Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, Zhan L, Li Y, Zhou ZG, Sun XF. Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Colorectal Dis 2012, 27(2):143-150. 10.1007/s00384-011-1302-9, 21870058.
44. Nodin B, Johannesson H, Wangefjord S, O'Connor DP, Lindquist KE, Uhlen M, Jirstrom K, Eberhard J. Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer. Diagn Pathol 2012, 7:115. 10.1186/1746-1596-7-115, 3523011, 22935204.
45. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3(5):421-429. 10.1016/S1535-6108(03)00110-7, 12781359.
46. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, et al. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444(7119):633-637. 10.1038/nature05268, 17136093.
47. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434(7035):864-870. 10.1038/nature03482, 15829956.
48. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA, Kastrinakis NG, Levy B, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434(7035):907-913. 10.1038/nature03485, 15829965.
49. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004, 432(7015):316-323. 10.1038/nature03097, 15549093.